Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31637017 | 1.00 | KMO (0.47) | KMOKDM4EASPHKDM8ALDH1A1 | |
| Lithium Ion SCHEMBL694807 | 0.82 | DHODH (0.34) | KMOKDM4EASPHKDM8MAPT | |
| SCHEMBL14771234 | 0.82 | NPSR1 (0.42) | KMOKDM4EMAPTNPSR1L3MBTL1 | |
| Zinc Ion SCHEMBL31116884 | 0.82 | DHODH (0.34) | KMOKDM4EASPHKDM8MAPT | |
| SCHEMBL31636805 | 0.79 | L3MBTL1 (0.46) | KDM4EALDH1A1MAPTALOX15NPSR1 | |
| SCHEMBL3548766 | 0.79 | MAPT (0.38) | KDM4EALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL439545 | 0.79 | KDM4E (0.47) | KMOKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL7199668 | 0.79 | KDM4E (0.47) | KMOKDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL19857487 | 0.78 | KDM4E (0.60) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL28313767 | 0.78 | KDM4E (0.46) | KMOKDM4EASPHKDM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| CN-113453764-B | 7H-pyrrolo [2,3-d ] pyrimidin-4-amine derivatives | 大鹏药品工业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| CN-113453764-A | 7H-pyrrolo [2,3-d ] pyrimidin-4-amine derivatives | 大鹏药品工业株式会社 | 2021-09-28 | — | — | CN | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| CN-109071593-B | Steroid derivative FXR agonist | 正大天晴药业集团股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2020166680-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 大鵬薬品工業株式会社 | 2020-08-20 | — | — | WO | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011141477-A1 | NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011073154-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-1928843-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | Amgen, Inc (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
| CN-1023479-C | Process for preparing monoamide derivatives of ethylenediamine | HOFFMANN LA ROCHE (CH) | 1994-01-12 | — | — | CN | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
| CN-85107182-A | Process for preparing monoamide derivatives of ethylenediamine | — | 1987-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KMO 1517/4885KDM4E 4483/4885ASPH 3386/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KMO 1517/4885KDM4E 4483/4885ASPH 3386/4885 |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KMO 1599/4885KDM4E 4472/4885ASPH 3660/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KMO 1517/4885KDM4E 4483/4885ASPH 3386/4885 |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | TIE1, KDR, BDKRB2 | KMO 499/4885KDM4E 648/4885ASPH 2237/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KMO 1517/4885KDM4E 4483/4885ASPH 3386/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KMO 1517/4885KDM4E 4483/4885ASPH 3386/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KMO 1517/4885KDM4E 4483/4885ASPH 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.